Improving Office Based Treatment of Opioid Use Disorder With Technology
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate whether using a novel drug-device combination to
deliver buprenorphine/naloxone (B/N) to patients in office-based treatment for Opioid Use
Disorder (OUD) is an effective way to improve compliance and treatment outcomes. The system
introduces psychological and behavioral supports in addition to securing the medication
between doses.
Phase:
N/A
Details
Lead Sponsor:
MedicaSafe, Inc.
Collaborators:
Artemis Institute for Clinical Research Friends Research Institute, Inc. Total Health Care
Treatments:
Analgesics, Opioid Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone